Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.40 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CASR | P41180 | 1/20 | 0.39 |
| ▸ | STS | P08842 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5264242 | 1.00 | MAPT (0.42) | MAPTLMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL3290098 | 0.91 | LMNA (0.42) | MAPTLMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL2294588 | 0.89 | ADRB3 (0.49) | MAPTADRB1ADRB3 | |
| SCHEMBL5261882 | 0.89 | ADRB3 (0.49) | MAPTADRB1ADRB3 | |
| SCHEMBL5264326 | 0.89 | ADRB3 (0.49) | MAPTADRB1ADRB3 | |
| SCHEMBL12380677 | 0.89 | ADRB3 (0.49) | MAPTADRB1ADRB3 | |
| Hydrochloric Acid SCHEMBL2294584 | 0.88 | ADRB3 (0.48) | MAPTLMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL3295260 | 0.88 | ATF4 (0.43) | MAPTLMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL5263928 | 0.88 | ATF4 (0.43) | MAPTLMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL5205600 | 0.86 | ADRB3 (0.50) | LMNAADRB1ADRB3CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718646-B2 | Cyclohexyl(alkyl)propanolamines, preparation method and pharmaceutical compositions containing same | SANOFI-AVENTIS (FR) | 2010-05-18 | — | — | US | claimed |
| US-20080261949-A1 | ethyl 4-[4-(2-hydroxy-3-(4-hydroxy-3-(methylsulphonylamino)phenoxy)propylamino)cyclohexyl]benzoic acid; beta-3 adrenergic receptor agonist; tocolytics; delaying preterm birth; antidiabetic; obesity; oxyalkylation of the phenyl(alkyl)cyclohexyl(alkyl)amine with a glycidyl ether | SANOFI-AVENTIS (FR) | 2008-10-23 | — | — | US | claimed |
| US-7419974-B2 | Cyclohexyl(alkyl)propanolamines, preparation method and pharmaceutical compositions containing same | SANOFI-AVENTIS (FR) | 2008-09-02 | — | — | US | claimed |
| EP-1341753-B1 | CYCLOHEXYL(ALKYL)-PROPANOLAMINES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SANOFI AVENTIS (FR) | 2007-09-26 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261949-A1 | ethyl 4-[4-(2-hydroxy-3-(4-hydroxy-3-(methylsulphonylamino)phenoxy)propylamino)cyclohexyl]benzoic acid; beta-3 adrenergic receptor agonist; tocolytics; delaying preterm birth; antidiabetic; obesity; oxyalkylation of the phenyl(alkyl)cyclohexyl(alkyl)amine with a glycidyl ether | ADRB3, FFAR3, ADRB2 | MAPT 4694/4885LMNA 346/4885MEN1 4724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.